Company to host conference call and webcast today at 8:00 a.m. ET--MIAMI, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Veru Inc.

Share on Pinterest Wegovy resolved liver inflammation in nearly two-thirds of participants in a major clinical trial, twice the rate seen with placebo. Steve Christo-Corbis/Getty Images Wegovy ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

Semaglutide and tirzepatide aid weight loss by mimicking gut hormones Ozempic, Wegovy, Mounjaro and Zepbound treat diabetes, support weight loss The weight loss drugs differ in FDA-approved uses ...

The U.S. Food and Drug Administration has accepted Novo Nordisk’s application for an oral version of its blockbuster weight loss drug Wegovy. The Danish drugmaker – which has its U.S ...

The FDA will decide whether to approve a once-daily, 25 mg oral formulation of semaglutide (Wegovy) by the end of 2025. If approved, it would be the first GLP-1 pill indicated for obesity ...

International study looked at 800 patients in 37 countries Patients getting the drug saw less inflammation and fat in their livers Lead researcher says it could help treat liver disease like MASH ...

If the U.S. Food and Drug Administration agrees to allow Novo Nordisk to expand the prescription’s label, Wegovy would become the first oral GLP-1 treatment for obesity management.

The GLP-1 RA may be either WEGOVY (semaglutide ... to be Available for Phase 3 Clinical Studies and Commercialization Veru is currently developing a novel, patentable, modified release oral ...